argenex (NASDAQ:ARGX) Issues Earnings Results, Beats Estimates By $0.36 EPS

argenex (NASDAQ:ARGX) issued its quarterly earnings results on Friday. The company reported $7.80 EPS for the quarter, topping analysts’ consensus estimates of $7.44 by $0.36, Zacks reports. The company had revenue of $1.75 billion during the quarter. argenex had a return on equity of 35.77% and a net margin of 31.66%.

argenex Price Performance

argenex stock opened at $873.71 on Friday. The stock has a market capitalization of $54.95 billion, a PE ratio of 30.49, a price-to-earnings-growth ratio of 0.79 and a beta of 0.44. The business has a 50 day simple moving average of $956.62 and a 200-day simple moving average of $885.37. argenex has a 12 month low of $661.85 and a 12 month high of $1,072.75.

Analyst Ratings Changes

A number of equities research analysts recently commented on ARGX shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of argenex in a report on Wednesday. DZ Bank reiterated a “buy” rating on shares of argenex in a research report on Friday, October 9th. Oppenheimer decreased their price objective on shares of argenex from $1,100.00 to $1,038.00 and set an “outperform” rating for the company in a research note on Monday, October 12th. Barclays reaffirmed a “buy” rating on shares of argenex in a report on Monday, September 7th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of argenex in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $1,142.37.

More argenex News

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Strong quarterly results: argenx reported $7.80 in EPS, exceeding the $7.44 consensus estimate, while revenue reached $1.75 billion. Product net sales grew 54% year over year to $1.7 billion, and operating profit was $486 million. argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Bullish analyst support: Morgan Stanley raised its price target from $1,140 to $1,190 and maintained an “overweight” rating. Wells Fargo also maintained “overweight” despite trimming its target from $1,356 to $1,336. Jefferies called the post-news setup a potentially attractive entry point. Morgan Stanley rating
• Neutral Sentiment: Targets remain above the market price, but revisions are mixed: Guggenheim lowered its target from $1,185 to $1,120 while keeping a “buy” rating. Robert W. Baird raised its target from $823 to $861 but retained a “neutral” rating, and RBC reportedly cut its target. These changes suggest continued confidence in long-term value but more cautious near-term expectations. Guggenheim rating
• Negative Sentiment: Clinical-development setback is overshadowing the earnings beat: Reports highlighted a surprise testing setback for argenx’s core drug, raising concerns about future growth, product expansion and execution. That issue appears to be driving the weaker investor reaction despite the company’s strong sales and profitability. argenx testing setback

argenex Company Profile

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.